Izzotti Alberto, Ceccaroli Chiara, Geretto Marta, Ruggieri Filippo Grillo, Schenone Sara, Di Maria Emilio
Department of Experimental Medicine, University of Genova, 16132 Genova, Italy.
IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Cancers (Basel). 2020 Jun 22;12(6):1652. doi: 10.3390/cancers12061652.
Colorectal cancer patients' responses to neoadjuvant therapy undergo broad inter-individual variations. The aim of this systematic review is to identify a molecular signature that is predictive of colon cancer downstaging and/or downgrading after neoadjuvant therapy. Among the hundreds analysed in the available studies, only 19 messenger-RNAs (mRNAs) and six micro-RNAs (miRNAs) were differentially expressed in responders versus non-responders in two or more independent studies. Therefore, a mRNA/miRNA signature can be designed accordingly, with limitations caused by the retrospective nature of these studies, the heterogeneity in study designs and the downgrading/downstaging assessment criteria. This signature can be proposed to tailor neoadjuvant therapy regimens on an individual basis.
结直肠癌患者对新辅助治疗的反应存在广泛的个体差异。本系统评价的目的是确定一种分子特征，以预测新辅助治疗后结肠癌的降期和/或降级。在现有研究分析的数百个指标中，在两项或更多独立研究中，只有19种信使核糖核酸（mRNA）和6种微小核糖核酸（miRNA）在反应者与无反应者中差异表达。因此，可据此设计一个mRNA/miRNA特征，但这些研究的回顾性性质、研究设计的异质性以及降期/降级评估标准会带来一定局限性。可以提出这种特征，以便根据个体情况定制新辅助治疗方案。
